Navin Rajagopalan Dmitry Abramov Kashvi Gupta Vidya Szymkowiak, MD John Mandrola, MD The relative risk reductions for the composite CV☠️/HF🏨 and for HF🏨 are similar for HFrEF and HFmrEF/HFpEF with SGLT2i

Primary composite:
The ARR was 3.1% in DELIVER
The ARR was 3.3% in EMPEROR-P

Patient-Centered Benefits>>Risks

Cost effectiveness analyses pending

Coincidental same-day release of 2 perspectives on the use of combo Rx in HF

Richard Lehman & Raj Mehta: podcasts.apple.com/us/podcast/ric…

yalecardiology GR:
youtube.com/watch?v=5gcO6n…

Most thankful that HF #ImpSci has taken center stage. Sanjay Kaul last line summarizes our task ahead 👇

#BP and Dapagliflozin in HFmEF/HFpEF #DELIVER
👉SBP <120 mmHg ↗️HF and ☠️ events
💊Dapagliflozin ⤵️SBP by 1.8mmHg vs placebo at 1-month
⚠️Adverse events between arms were similar across SBP categories
👉Beneficial effects of dapagliflozin were not accounted for the changes in SBP

ICYMI - Thought-provoking and masterful yalecardiology grand rounds by Muthu Vaduganathan Brigham and Women's Hospital.

Making the case for upfront combination therapy to optimize outcomes in cardiometabolic diseases.

You can watch them here:
youtube.com/watch?v=5gcO6n…

Happening Now: 'Upfront Combination Medical Therapy in Cardiometabolic Disease Management: One Size Fits Many?' Watch Yale Cardiovascular Medicine Grand Rounds with Muthu Vaduganathan.

youtube.com/watch?v=5gcO6n…

Yale School of Medicine Yale Internal Medicine Rohan Khera

Terrific yalecardiology Grand Rounds talk by Muthu Vaduganathan...questioning conventional wisdom in cardiology. Why do we escalate treatments over months instead of treating with all effective medications in combination? Evidence emerging for early combination therapy. Yale School of Medicine

🔥 #EMPEROR_PROGRAMME
Empa effect on circulating proteomics in #HF
🧐 Analysis of a group on intracellular proteins that shows #Cardio_Renal_Protection
⬆️ Authophagic flux
⬇️ Inflammation & Oxidative stress
⬆️ Heart & kidney repair 🛡
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦
shorturl.at/mqswX

Ever wondered if finereone does anything to BP in resistant hypertension? Here is an indirect comparison study (AMBER vs FIDELITY-RHTN) that shows a smaller BP reduction with finerenone compared to spironolactone, but also lower risk of hyperkalemia. academic.oup.com/ckj/advance-ar…

Long-term treatment with #dapagliflozin extends event-free survival by up to 2.0 to 2.5 years among middle aged and older individuals with #HFmrEF , #HFpEF or #HFimpEF

jacc.org/doi/10.1016/j.…

Michael Nassif James Januzzi Jr MD Muthu Vaduganathan scottdavidsolomon Carolyn Lam #HeartFailure

Clinical inertia may contribute to inadequate care in patients with #cardiometabolic disease. Muthiah Vaduganathan, MD, MPH, explores the merits of upfront combination medical therapy.

📅 TUE 1 NOV
⏰ 8am ET
🎙️ hosted by Rohan Khera

Grand Rounds info: buff.ly/3TUkWrV

📌Estimated Long-Term Benefit of #Dapagliflozin in Patients w/ #HeartFailure

#CardioTwitter #CardioEd

Estimated Long-Term Benefit of Dapagliflozin in Patients With #HF #DELIVER
👥6,263
👉 survival free from the primary endpoint for a 65-year-old 👥 was 12.1 years with dapagliflozin vs 9.7 years with placebo
👉➕ a 2.3-year event-free survival gain Soc Esp Cardiología

🎙️New episode available in our Heart Failure in Focus podcast!

In this month's episode, Dr Biykem Bozkurt joins us to answer some of the most challenging questions around implementing guideline-directed medical therapy (GDMT).

ow.ly/wY3x50LpHV6

#Cardiology #HeartFailure

After 14 wonderful years at Brigham and Women's Hospital, Mass General Brigham, Dana-Farber, and VA Boston HC, I am happy to announce that I will be the Director of Mount Sinai Heart at Mount Sinai Health System and the Dr. Valentin Fuster Professor of CV Medicine at Icahn School of Medicine at Mount Sinai. mountsinai.org/about/newsroom…

🚨 New #SimPub #AHA22 led by Duke IM Residency Jake Pierce

*⃣ #ARNI use for HFmrEF/HFpEF has increased over time, but absolute use remains low

*⃣ ARNI prescription concentrated at select US hospitals

AHAMeetings AHA Science #GWTG_HF Duke Clinical Research Institute Circ: Heart Failure

ahajournals.org/doi/10.1161/CI…